Premium
Overexpression of BMI ‐1 is associated with poor prognosis in cervical cancer
Author(s) -
Tong YongQing,
Liu Bei,
Zheng HongYun,
He YuJuan,
Gu Jian,
Li Feng,
Li Yan
Publication year - 2012
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2012.01564.x
Subject(s) - cervical cancer , medicine , immunohistochemistry , oncology , metastasis , breast cancer , cancer , biomarker , clinical significance , pathology , cancer research , biology , biochemistry
Aim It has been reported that BMI‐1, a gene transcription promoter overexpressed in various human cancers, is associated with poor survival. We investigated whether BMI‐1 is a marker for cervical cancer by detecting the expression of BMI‐1 in cervical cancer. Methods An immunohistochemistry (IHC) streptavidin‐peroxidase technique was used to identify BMI‐1 protein expression in 302 cervical cancer specimens. Reverse transcription polymerase chain reaction and Western blot were employed to measure BMI‐1 mRNA and protein level. The correlation between BMI‐1 expression and clinicopathological factors was analyzed. Results Both BMI‐1 mRNA and protein expression were evident in cervical carcinoma tissues. An intense positive rate of 55.3% (167/302) was observed by IHC. High BMI‐1 expression was correlated with clinical stage, lymph node metastasis, vascular invasion and human papillomavirus (HPV) infection ( P < 0.05), but there is insufficient evidence to confirm its value in tumor size, age, estrogen or progesterone receptor ( P > 0.05). The BMI‐1 protein level was positively correlated with the clinical stages of cervical carcinoma and a high BMI‐1 expression was associated with poor prognosis ( P < 0.05). Conclusion The high expression of BMI‐1 in cervical cancer is related to tumor progression, lymph node metastasis and HPV infection, suggesting that cervical cancer with excessive BMI‐1 expression possesses high metastases potential and that BMI‐1 may be a promising biomarker for predicting metastasis in cervical cancer.